Drug Profile
GED aPC
Alternative Names: GED-aPC; LY458202Latest Information Update: 15 Apr 2013
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Protein C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Cardiogenic shock
Most Recent Events
- 23 Nov 2010 Suspended - Phase-I for Cardiogenic shock in Canada (IV)
- 25 Sep 2009 Cardiome is seeking inverstors and/or partners to fund the development of GED aPC \http://www.cardiome.com/index.php\
- 24 Mar 2009 Phase-I development is ongoing in Canada